Oncology
The presence of specific microbes in the gut microbiota can serve as biomarkers for predicting the efficacy of immunotherapy.
Specific gut microbiota features correlate with better responses to immunotherapy in people with melanoma.
The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.
This article presents “The Cancer Microbiota Database," an interactive and customizable tool to investigate 33 types of cancers.
Microbiomepost discussed with Lisa Derosa, oncologist at Gustave Roussy Hospital in Paris, about the link between gut dysbiosis and cancer, shedding light on its role in immunotherapy resistance and patient…
The findings suggest that the microbiota processes environmental carcinogens in ways that lead to cancer.
The findings support the idea that the gut microbiota modulates immune responses, suggesting new avenues for cancer treatment.
The balance of specific microbes in the gut can help predict who will respond to immunotherapy drugs.
The findings of a recent study suggest that the combination of anti-PD-1 immunotherapy with a lack of TREM2 generates a gut environment that promotes inflammation, which improves tumor rejection.
The findings of a recent study suggest that Desulfovibrio can drive cancer progression, paving the way for therapeutic approached that targeting the gut microbiota.
